C基因截短突变体抗乙型肝炎病毒作用机制的研究

目的 探讨C基因截短突变体抗乙型肝炎病毒(HBV)的作用机制。方法 构建C基因截短的真核表达载体pcDNA3-△C及野生型C基因真核表达载体pcDNA3-C，瞬时转染HepG2细胞，用SDSPAGE western blot检测pcDNA3-△C、pcDNA3-C的蛋白表达。pcDNA3-△C与adwR9共转染HepG2细胞，以pcDNA3与adwR9为对照，用荧光定量PCR检测培养上清液及细胞内病毒量，用Native western blot分析C基因截短蛋白干扰核心颗粒形成。结果重组载体pcDNA3-△C、pcDNA3-C均可表达，DcDNA3-△C与adwR9共转染组上清液和细胞内病毒量较对照组降低，pcDNA3-△C和pcDNA3-C共转染组Native western blot条带与pcDNA3和pcDNA3-C共转染组条带相比较明显淡。结论 C基因截短突变体可干扰核心颗粒的形成，导致HBV复制下降。     

HBV pre-X转染HepG2细胞后差异表达基因的筛选

目的:检测HBV Pre-X在真核表达栽体PcDNA3.1-myc-his-HBV pre-X转染的HepG2细胞中的表达,并筛选其中的代谢相关差异表达基因.方法:将构建的真核表达载体pcDNA3.1-mychis-HBV pre-X转染HepG2细胞后蛋白免疫印迹检测:将pcDNA3.1-myc-his-HBV pre-X和pcDNA3.1-myc-his载体分别转染HepG2细胞后,提取mRNA后逆转录为cDNA,运用基因表达谱芯片技术分析差异表达基因.结果:构建的真核表达载体经ApsI、BstXI双酶切鉴定,转染HepG2细胞后HBV pre-X表达经蛋白免疫印迹证实:经基因表达谱芯片分析发现,其中基因表达水平显著上调和下调的分别是200个和62个.结论:筛选HBV pre-X转染HepG2细胞后的代谢相关差异表达基因,从而为乙型肝炎病毒合并糖尿病、脂肪肝等代谢性疾病的分子生物学机制的研究提供了重要依据.     

包膜蛋白和核心蛋白共突变体对乙型肝炎病毒在 HepG2细胞中表达的抑制作用

目的探讨包膜蛋白和核心蛋白共突变体对乙型肝炎病毒(HBV)在HepG2细胞中表达的抑制作用。方法构建包膜蛋白和核心蛋白共突变的HBV载体pHBV-mSIS／△C。瞬时转染HepG2细胞,以adwR9转染HepG2细胞为对照;用ELISA方法检测上清液中和细胞内HBV S抗原;重组载体与adwR9共转染HepG2细胞,以pcDNA3与adwR9共转染为对照组。用荧光定量PCR检测胞内和上清液中病毒量。结果突变载体转染细胞胞内和上清液中S蛋白表达量及分泌量与adwR9无明显差别;突变载体与adwR9共转染组上清液和胞内病毒量较pcDNA3与adwR9共转染组低。结论包膜蛋白和核心蛋白共突变对HBV S蛋白的表达量和分泌量没有影响,但干扰病毒复制和包装,具有抗HBV作用。     

乙型肝炎病毒前-S2蛋白下调诱导型一氧化氮合酶基因启动子的转录活性

目的探讨乙型肝炎病毒(HBV)前-S2(pre-S2)蛋白对诱导型一氧化氮合酶(iNOS)基因启动子转录的调节作用。方法利用生物信息学技术确定iNOS基因的启动子区域(iNOSp)和3个缺失突变体的基因序列,聚合酶链反应(PCR)分别扩增iNOSp和3个缺失突变体的基因序列,分别克隆至报告基因表达载体pCAT3-Basic中,构建pCAT3-iNOSp载体;以构建的这4种报告基因表达载体,分别转染人肝母细胞瘤细胞系HepG2,用酶联免疫吸附法(ELISA)检测氯霉素乙酰转移酶(CAT)的表达活性;并与真核表达载体pcDNA3.1(-)-HBV pre-S2共转染HepG2细胞系,用ELISA法检测CAT的表达活性。结果成功获得iNOS基因启动子和3个缺失突变体的正确克隆,p1-iNOSp、p3-iNOSp启动子和pcDNA3.1 (-)-HBV pre-S2瞬时共转染HepG2细胞时,iNOS启动子的转录活性明显下降,HBV pre-S2蛋白对p1- iNOSp、p3-iNOSp表达活性的抑制率分别是54.7%和79.5%,p2-iNOSp、p4-iNOSp与pcDNA3.1(-)-HBV pre-S2共转染HepG2细胞后,HBV pre-S2蛋白对p2-iNOSp、p4-iNOSp表达活性没有明显的调节作用。重复试验得到了相似的结果。结论HBV pre-S2蛋白在细胞内的表达对iNOS启动子的转录活性具有明显的下调作用。     

HIV-1B亚型核心蛋白gag基因真核表达载体的构建及其在HepG2细胞中的表达

目的克隆人类免疫缺陷病毒Ⅰ型B亚型核心蛋白gag基因,构建真核表达载体,并在真核细胞中表达,为进一步制备自行设计的以λ噬菌体作为载体的HIV核酸疫苗奠定基础。方法以克隆好的HIV1B亚型U26942全基因质粒DNA作为模板,根据Genbank中gag基因的核苷酸序列设计引物,并在引物的5’端分别引入BamHⅠ及XhoⅠ酶切位点,特异性的扩增gag基因。TA克隆后经双酶切、测序等鉴定重组质粒,再经双酶切、连接构建含gag编码基因的真核表达载体,并进行酶切鉴定分析pcDNA3.1(+)/gag。在脂质体介导下转染HepG2细胞,经G418压力筛选建立稳定转染gag基因的细胞系,用RT PCR及Western印迹检测其在HepG2细胞中的表达。结果重组质粒经BamHⅠ、XhoⅠ双酶切成5.4kb与1.5kb的片断,表明表达载体pcDNA3.1(+)中插入了gag基因片断,测序结果表明编码框正确。RT PCR及Western印迹证实稳定转染gag基因的HepG2细胞系中有该基因的表达。结论成功构建了HIV1B亚型核心蛋白gag基因的真核表达载体pcDNA3.1(+)/gag,并在HepG2细胞中获得稳定表达。     

HCV核心基因转染HepG2细胞后基因表达差异筛选

目的将真核表达载体pcDNA3.1(-)HCV core转染到HepG2细胞,在HepG2细胞中表达HCV核心蛋白,并筛选其中的差异表达基因。方法将构建的真核表达载体pCDNA3.1(-)HCVcore转染HepG2细胞后进行蛋白免疫印迹检测;将pcDNA3.1(-)HCVcore和pcDNA3.1(-)载体分别转染HepG2细胞后,提取mRNA并逆转录为cDNA,运用基因表达谱芯片技术分析差异表达基因。结果构建的真核表达载体经双酶切鉴定;转染HepG2细胞后HCV核心蛋白表达经蛋白免疫印迹证实;经基因表达谱芯片分析发现,其中基因表达水平显著上调和下调的分别是181个和48个。结论筛选HCV核心基因转染HepG2细胞后的糖类和脂类物质代谢相关的差异表达基因,从而为丙型肝炎病毒合并糖尿病、脂肪肝等代谢性疾病的分子生物学机制的研究提供了重要依据。     

携带IFN-5α基因的HBV DNA质粒构建及其表达

目的构建携带人IFN-5α基因的X基因缺陷的HBV DNA真核表达质粒，并在真核细胞中表达。方法在pBR322-B-HBV质粒(含adr Ⅰ型HBV DNA)中插入人工合成片段破坏其HBV—X基因区，再与IFN-5α片段连接，最后克隆入真核表达载体pcCNA3，获得携带人IFN-5α基因的X基因缺陷的HBV DNA真核表达质粒pcDNA3-KN-F1F2-IFN-5α。同时构建两组对照质粒，即连接完整HBV DNA的真核表达质粒和连接X基因缺陷的HBV DNA真核表达质粒，将上述3种质粒以脂质体法同时转染HepG2细胞，G418筛选出稳定表达系统后选用荧光定量PCR法、ELISA法、RT-PCR法检测3种包装病毒。的复制表达以及IFN-5α的表达水平。结果获得目的真核表达质粒pcDNA3-KN—F1F2-IFN-5α；目的质粒转染HepG2细胞后其包装病毒的复制表达水平均较两个对照组降低；插入的IFN-5α片段可以在mRNA以及蛋白质水平表达。结论成功构建携带人IFN-5α基因的X基因缺陷的HBVDNA真核表达质粒，并能在HepG2真核细胞中表达。     

乙型肝炎病毒DNA聚合酶N末端蛋白基因芯片研究

目的:检测乙型肝炎病毒(HBV)DNA聚合酶N末端蛋白(TP) 的表达对肝母细胞瘤细胞HepG2基因表达谱的影响,进一步阐明TP在乙型肝炎陧性化及致肝细胞癌发生发展过程中的分子生物学机制. 方法:根据AF384372 HBVDNA病毒株序列设计、合成HBV DNA P-TP基因序列特异性的引物,以含有AF384372HBVDNA P全基因组cDNA的质粒G318A7作为模板,应用聚合酶链反应(PCR)技术扩增TP蛋白编码基因片段,以常规的分子生物学技术将获得的HBV DNA-TP 编码基因片段克隆到TA载体中进行核苷酸序列的测定, 构建真核表达载体pcDNA3.1(-)-TP.以脂质体转染肝母细胞瘤细胞系HepG2,提取mRNA,逆转录为cDNA,与转染空白表达载体pcDNA3.1(-)的HepG2细胞进行DNA芯片分析. 结果:构建的表达载体经过限制性内切酶分析和DNA序列测定,证实准确无误.以单链可变区抗体的Western blot杂交技术证实构建的表达载体转染HepG2细胞之后有TP蛋白的表达,提取高质量的mRNA并进行逆转录成为cDNA,进行DNA 芯片技术分析.在1 152个基因表达谱的筛选中,发现有111 个基因表达水平显著上调,88个基因表达水平显著下调. 结论:应用基因表达谱芯片成功筛选了HBV DNA P-TP转染细胞后差异表达基因,为进一步阐明TP蛋白致病的分子生物学机制提供依据.     

核心蛋白聚糖真核表达载体的构建及其在A549中的表达

目的 建立人核心蛋白聚糖(decorin,DCN) 真核表达载体,并在A549细胞中进行表达,为进一步研究其抗肿瘤作用奠定基础.方法 用PCR法扩增出DCN分子编码序列的cDNA全长,与pcDNA3.1(+)载体连接,构建真核表达载体pcDNA3.1-decorin,并转化到大肠杆菌JM109中扩增以获得重组载体,应用双酶切、PCR以及测序鉴定此重组载体;脂质体介导重组载体转染A549细胞,经G418筛选建立稳定转染细胞株,分别采用RT-PCR、免疫组化法和Western印迹法检测其表达.结果 获得了约1 080 bp大小的特异性DNA片段;PCR产物与真核表达载体进行连接,经过双酶切、PCR以及测序鉴定证实分泌型DCN cDNA片段正确插入真核表达载体pcDNA3.1中.RT-PCR方法可见转染组mRNA表达明显增多,免疫组化和Western印迹方法可见转染组细胞DCN蛋白表达明显增高.结论 成功构建了真核表达载体pcDNA3.1-decorin,建立了稳定转染DCN的A549细胞株.     

核心蛋白聚糖在HepG2细胞中的表达及作用

目的 构建分泌型核心蛋白聚糖(DCN)真核表达载体,并观察其在肝癌细胞HepG2中的表达和抗肿瘤作用.方法 应用PCR技术扩增DCN全长基因eDNA片段,与pcDNA3.1载体连接,并转化到大肠杆菌中扩增获得重组载体,应用双酶切、PCR以及测序鉴定此重组载体,脂质体介导转染HepG2,经G418筛选建立稳定转染细胞株,采用RT-PCR、免疫组化检测其表达.MTT检测细胞增殖活力,流式细胞仪分析细胞周期.结果 RT-PCR可见转染组细胞mRNA表达明显增多,免疫组化可见转染组细胞DCN蛋白表达明显增高.细胞生长曲线显示转染组细胞生长缓慢,G,期细胞显著增多.结论 本方法可成功建立稳定转染DCN的HepG:细胞株,并证实DCN能够抑制HepG:细胞株的生长.     

Construction and expression of eukaryotic plasmids containing lamivudine-resistant or wild-type strains of Hepatitis B Virus genotype C

AIM： To construct eukaryotic expression plasmids of full-length Hepatitis B Virus （HBV） genotype C genome, which contain lamivudine-resistant mutants （YIDD, YVDD） or wild-type strain （YMDD）, and to observe the expression of HBV DNA and antigens [hepatitis B surface antigen （HBsAg） and hepatitis B e antigen （HBeAg）] of the recombinant plasmids in HepG2 cells. METHODS： Three HBV full-length genomes were amplified from the plasmids pMD18T-HBV/YIDD, pMD18T-HBV/YVDD and pMD18T-HBV/YMDD, using PCR. Three recombinant plasmids were generated by inserting each of the PCR products into the eukaryotic expression vector pcDNA3.1 （＋）, between the EcoRI and HindⅢ sites. After being characterized by restriction endonuclease digestion, and DNA sequence analysis, the recombinant plasmids were transfected into HepG2 cells. At 48 and 72 h post-transfection, the levels of intracellular viral DNA replication were detected by real-time PCR, and the expression of HBsAg and HBeAg in the cell culture supernatant was determined by ELISA.
RESULTS： Restriction endonuclease digestion and DNA sequence analysis confirmed that the three recombinant plasmids were correctly constructed. After transfecting the plasmids into HepG2 cells, high levels of intracellular viral DNA replication were observed, and HBsAg and HBeAg were secreted into the cell culture supernatant.
CONCLUSION： Eukaryotic expression plasmids pcDNA3.1 （＋）-HBV/YIDD, pcDNA3.1 （＋）-HBV/YVDD or pcDNA3.1 （＋）-HBV/YMDD, which contained HBV genotype C full-length genome, were successfully constructed. After transfection into HepG2 cells, the recombinant plasmids efficiently expressed HBV DNA, HBsAg and HBeAg. Our results provide an experimental basis for the further study of HBV lamivudine-resistant mutants.     

羧基末端截短的HBV表面抗原中蛋白反式激活c-myc表达

目的构建羧基末端截短的乙型肝炎病毒表面抗原中蛋白（MHBst）反式激活基因的消减文库，并观察其对细胞原癌基因c-myc的反式激活作用。方法以重组表达质粒pcDNA3．1（-）．MHBst和空载体pcDNA3．1（-）瞬时转染HepG2细胞，提取细胞mRNA并逆转录为cDNA，分别标记为实验组与对照组，应用抑制性消减杂交技术，构建MHBst反式激活的cDNA消减文库。针对其中的原癌基因c-myc，进一步克隆其启动子序列并构建报告基因表达载体pCAT3．c-myc，与pcDNA3．1（-）．MHBst共转染HepG2细胞，ELISA法检测报告基因氯霉素乙酰转移酶CAT的表达活性。同时，应用反转录聚合酶链反应和免疫印迹方法检测表达MHBst的细胞中c-myc基因的mRNA转录和蛋白表达水平。结果随机挑选消减文库中的50个阳性克隆进行测序和生物信息学分析，显示19种已知功能基因，涉及细胞代谢、信号转导、细胞凋亡和肿瘤发生等生物学过程。细胞内瞬时表达的MHBst蛋白能够反式激活细胞原癌基因c-myc启动子的转录活性，并且RT-PCR和Western blotting结果也证明了表达MHBst蛋白的细胞中原癌基因c-myc的表达水平明显增强。结论成功构建MHBst反式激活基因的消减文库，MHBst可以反式激活细胞原癌基因c-myc的表达，为深入了解乙型肝炎病毒致癌的分子生物学机制提供理论基础。     

HBsAg真核表达质粒及其诱导的小鼠特异性免疫应答

目的 研究HBsAg真核表达质粒pCI-S和pcDNA3.1-S在真核细胞中的表达和质粒DNA的免疫效果。方法 应用基因重组技术构建HBsAg真核表达质粒pCI-S和pcDNA3.1-S；经酶切和测序鉴定无误后，用阳离子脂质体介导的方法将重组质粒转染HepG2和COS-7细胞，48h后，再ELISA的方法检测重组质粒在细胞中HBsAg的表达，同时同质粒DNA免疫小鼠，用ELISA检测免疫小鼠血清抗-HBs抗体水平；用乳酸脱氢酶释放法检测小鼠肿瘤细胞HBsAg特异性CTL反应。结果 重组质粒pCI-S和pcDNA3.1-S转染的HepG2和COS-7细胞培养上清液和sAg均为阳性。DNA免疫小鼠血清可检测到高滴度的抗-HBs抗体，免疫小鼠脾细胞可检测到校强的HBsAg特异性CTL反应。结论 HBsAg真核表达质粒pCI-S和pcDNA3.1-S可在HepG2和COS-7细胞中高效表达，DNA免疫小鼠成功地诱导出抗-HBs和HBsAg特异性CTL反应。     

Study of transactivating effect of pre-S2 protein of hepatitis B virus and cloning of genes transactivated by pre-S2 protein with suppression subtractive hybridization

AIM: To investigate the transactivating effect of pre-S2 protein of hepatitis B virus (HBV) and construct a subtractive cDNA library of genes transactivated by pre-S2 protein with suppression subtractive hybridization (SSH) technique, and to pave the way for elucidating the pathogenesis of HBV infection. METHODS: pcDNA3.1(-)-pre-S2 containing pre-S2 region of HBV genome was constructed by routine molecular methods. HepG2 cells were cotransfected with pcDNA3.1 (-)-pre-S2/pSV-lacZ and empty pcDNA3.1(-)/pSV-lacZ. After 48 h, cells were collected and detected for the expression of β-galactosidase (β-gal). SSH and bioinformatics techniques were used, the mRNA of HepG2 cells transfected with pcDNA3.1(-)-pre-S2 and pcDNA3.1(-) empty vector was isolated, respectively, cDNA was synthesized. After digestion with restriction enzyme RsaI, cDNA fragments were obtained. Tester cDNA was then divided into two groups and ligated to the specific adaptor 1 and adaptor 2, respectively. After tester cDNA was hybridized with driver cDNA twice and underwent two times of nested PCR, amplified cDNA fragments were subcloned into pGEM-Teasy vectors to set up the subtractive library. Amplification of the library was carried out with E.coli strain DH5oα. The cDNA was sequenced and analyzed in GenBank with Blast search after PCR. RESULTS: The pre-S2 mRNA could be detected in HepG2 cells transfected with pcDNA3.1(-)-pre-S2 plasmid. The activity of β-gal in HepG2 cells transfected with pcDNA3.1 (-)-pre-S2/pSV-lacZ was 7.0 times higher than that of control plasmid (P<0.01). The subtractive library of genes transactivated by HBV pre-S2 protein was constructed successfully. The amplified library contains 96 positive clones. Colony PCR showed that 86 clones contained 200-1 000 bp inserts. Sequence analysis was performed in 50 clones randomly, and the full length sequences were obtained with bioinformatics method and searched for homologous DNA sequence from GenBank, altogether 25 coding sequences were obtained, these cDNA sequences might be the target genes transactivated by pre-S2 protein. CONCLUSION: The pre-S2 protein of HBV has transactivating effect on SV40 early promoter. The obtained sequences may be target genes transactivated by pre-S2 protein among which some genes coding proteins involved in cell cycle regulation, metabolism, immunity, signal transduction and cell apoptosis.This finding brings some new clues for studying the biological functions of pre-S2 protein and further understanding of HBV hepatocarcinogesis.     

HBV X基因-HCV C基因cDNA融合基因真核表达载体的构建及其表达

目的：构建HBV X-HCV C融合基因真核表达载体，并获得稳定表达该基因的HepG2细胞株。方法：双酶切质粒pXT1-X，得到完整的HBV X基因片段后，将其插入到质粒PBK-CMV和PBK-HCVC的相应酶切位点，得到重组质粒PBK-X和PBK-X-C；再将质粒RBK-CMV、PBK-X、PBK-HCV C和PBK-X-C分别导入肝癌细胞株HepG2中，G418筛选，RT-PCR、蛋白印迹鉴定HBV X和HCV C蛋白表达。结果：质粒PBK-CMV、PBK-X、PBK-HCV C和PBK-X-C在HepG2细胞中有稳定表达。结论：成功构建HBV X-HCVC融合基因真核表达载体，并获得稳定表达该基因的HepG2细胞株。     

编码弓形虫表面抗原P30、P22复合基因真核表达载体的构建

目的　构建编码弓形虫RH株表面抗原P30、P22复合基因的真核表达重组质粒, 为进一步表达融合蛋白及研制核酸疫苗做准备。　方法　用弓形虫RH株腹腔接种小鼠,收集腹水,酚/氯仿法抽提弓形虫基因组 DNA;用 PCR技术从基因组DNA中扩增编码表面抗原 P30、P22 的基因片段,分别重组入 pMD18 T载体中。将 pMD18 T载体中的P30、P22基因片段分别酶切,定向克隆入 pUC18克隆载体中, pUC18 P30 P22 中的 P30 P22 片段经酶切、纯化后,亚克隆入 pcDNA3.1( )真核表达载体,用酶切、PCR及测序的方法对重组子进行鉴定。　结果　从弓形虫 RH株基因组DNA中扩增出特异的P30及P22片段;大小均与预测值相符;克隆 pUC18 P30 P22 重组质粒的酶切片段分别与 P30、P22基因大小一致;经亚克隆、筛选鉴定获得了 pcDNA3.1 P30 P22重组质粒,所测P30、P22基因序列与文献报道一致。结论　成功构建弓形虫 pUC18 P30 P22重组质粒和 pcDNA3.1 P30 P22 重组质粒,为研制弓形虫 DNA疫苗奠定了基础。     

Transactivating effect of hepatitis C virus core protein： A suppression subtractive hybridization study

AIM: To investigate the transactivating effect of hepatitis C virus (HCV) core protein and to screen genes transactivated by HCV core protein. METHODS: pcDNA3.1(-)-core containing full-length HCV core gene was constructed by insertion of HCV core gene into EcoRI/BarnHI site. HepG2 cells were cotransfected with pcDNA3.1(-)-core and pSV-lacZ. After 48 h, cells were collected and detected for the expression of β-gal by an enzyme-linked immunosorbent assay (ELISA) kit. HepG2 cell swere transiently transfected with pcDNA3.1(-)-core using Upofectamine reagent. Cells were collected and total mRNA was isolated. A subtracted cDNA library was generated and constructed into a pGEM-Teasy vector. The library was amplified with E. coil strain JM109. The cDNAs were sequenced and analyzed in GenBank with BLAST search after polymerase chain reaction (PCR). RESULTS: The core mRNA and protein could be detected in HepG2 cell lysate which was transfected by the pcDNA3.1(-)-core. The activity of β-galactosidase in HepG2 cells transfected by the pcDNA3.1(-)-core was 5.4 times higher than that of HepG2 cells transfected by control plasmid. The subtractive library of genes transactivated by HCV core protein was constructed successfully. The amplified library contained 233 positive clones. Colony PCR showed that 213 clones contained 100-1 000 bp inserts. Sequence analysis was performed in 63 clones. Six of the sequences were unknown genes. The full length sequences were obtained with bioinformatics method, accepted by Genl3ank. It was suggested that six novel cDNA sequences might be target genes transactivated by HCV core protein. CONCLUSION: The core protein of HCV has transactivating effects on SV40 early promoter/enhancer. A total of 63 clones from cDNA library were randomly chosen and sequenced. Using the BLAST program at the National Center for Biotechnology Information, six of the sequences were unknown genes. The other 57 sequences were highly similar to known genes.     

丙型肝炎病毒1b基因型核心蛋白对HepG2细胞Bax与Bcl-2基因表达的影响

目的研究丙型肝炎病毒（HCV）1b基因型核心蛋白（C）对HepG2细胞B细胞淋巴瘤-2基因（Bcl-2）与Bcl-2相关X蛋白（Bax）表达的影响,以探索1b型HCV C蛋白与HepG2细胞凋亡的关系。方法利用RT-PCR扩增出HCV-1b-C基因,经双酶切后连接pcDNA3.1（-）,成功构建真核表达载体pcDNA3.1（-）/HCV-1b-C。利用脂质体转染HepG2细胞,RT-PCR及Western Blot检测其mRNA及蛋白的表达,RT-PCR及Western Blot检测转染成功后HCV-1b-C对HepG2细胞Bax与Bcl-2表达的影响,并设转染空质粒组及未处理组作对照。结果成功构建真核表达载体pcDNA3.1（-）/HCV-1b-C;瞬时转染HepG2细胞,成功表达HCV C mRNA及蛋白;转染C基因组的Bax的mRNA及蛋白相对表达量减少,与转染空质粒组及未处理组比较差异均有统计学意义（P〈0.01）;转染C基因组的Bcl-2的mRNA及蛋白相对表达量增多,与转染空质粒组及未处理组比较差异均有统计学意义（P〈0.01）。结论 1b基因型HCV C蛋白转染HepG2细胞会导致Bax表达减少及Bcl-2表达增多,降低Bax/Bcl-2比值,可能是抑制HepG2细胞凋亡的机制之一。     

应用基因芯片技术对乙型肝炎病毒DNA聚合酶反式调节基因的研究

目的应用基因表达谱芯片(基因芯片)技术检测乙型肝炎病毒DNA聚合酶(HBVDNAP)三个功能域[(N末端蛋白(TP),逆转录酶DNA多聚酶(PR),核糖核酸酶H(RNaseH)]的表达对肝母细胞瘤细胞HepG2基因表达谱的影响,进一步阐明HBVDNAP对肝细胞基因表达的调节机制及其生物学功能。方法以常规分子生物学技术分别构建真核表达载体pcDNA3.1()TP,pcDNA3.1()PR和pcDNA3.1()RNaseH,以脂质体转染肝母细胞瘤细胞系HepG2,提取mRNA,逆转录为cDNA,与转染空白表达载体pcDNA3.1()的HepG2细胞进行DNA芯片分析。结果TP有111条基因表达水平上调,88条基因表达水平下调。PR有79条基因表达水平上调,90条基因表达水平下调。RNaseH有113条基因表达水平上调,109条基因表达水平下调。结论应用基因芯片成功筛选HBVDNAP三个功能域蛋白转染细胞后的差异表达基因,为进一步研究HBVDNAP的反式激活作用及免疫调节机制提供了新的依据。